BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
Related news for (BICX)
- BioCorRx Reports Business Update for the Second Quarter of 2024
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
- BioCorRx Reports Business Update for 2023
- BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD